SCHEMBL7120286

SCHEMBL7120286

O=C(Nc1ccc(Cl)cc1)c1ccccc1NS(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC20A2 Q08357 1/20 0.74
SLC20A1 Q8WUM9 1/20 0.74
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
GAA P10253 1/20 0.67
RXFP1 Q9HBX9 9/20 0.61
KDM4E B2RXH2 2/20 0.60
GPR27 Q9NS67 2/20 0.56
AVPR2 P30518 1/20 0.56
SLC10A2 Q12908 2/20 0.53
SLC10A1 Q14973 2/20 0.53
SLC10A6 Q3KNW5 2/20 0.53
LMNA P02545 2/20 0.53
ACLY P53396 1/20 0.53
ALDH1A1 P00352 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
CRHBP P24387 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128448 0.91 MEN1 (0.76) SLC20A2SLC20A1MEN1KMT2AGAA
SCHEMBL30926577 0.91 MEN1 (0.76) SLC20A2SLC20A1MEN1KMT2AGAA
SCHEMBL30926819 0.90 MEN1 (0.68) SLC20A2SLC20A1MEN1KMT2AGAA
SCHEMBL27181165 0.90 MEN1 (0.68) SLC20A2SLC20A1MEN1KMT2AGAA
SCHEMBL28454669 0.90 MEN1 (0.64) SLC20A2SLC20A1MEN1KMT2AGAA
SCHEMBL23200355 0.89 MEN1 (0.67) SLC20A2SLC20A1MEN1KMT2AGAA
SCHEMBL30926890 0.89 MEN1 (0.67) SLC20A2SLC20A1MEN1KMT2AGAA
SCHEMBL5119995 0.89 RXFP1 (0.70) SLC20A2SLC20A1MEN1KMT2ARXFP1
SCHEMBL7631719 0.85 SLC20A2 (0.86) SLC20A2SLC20A1MEN1KMT2AGAA
SCHEMBL7128814 0.85 SLC20A2 (1.00) SLC20A2SLC20A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216449-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-20 US claimed
EP-1187531-A4 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-05-28 EP claimed
US-6458845-B1 METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A SMITHKLINE BEECHAM CORPORATION 2002-10-01 US claimed
EP-1202729-A1 PHOSPHATE TRANSPORT INHIBITORS SmithKline Beecham Corporation (US) 2002-05-08 EP claimed
EP-1187531-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-20 EP claimed
WO-2001098264-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-27 WO claimed
WO-2001087294-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-22 WO claimed
WO-2001005398-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-01-25 WO claimed
WO-2000078145-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-28 WO claimed
US-20030216449-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-20 US disclosed
EP-1202729-A1 PHOSPHATE TRANSPORT INHIBITORS SmithKline Beecham Corporation (US) 2002-05-08 EP disclosed
WO-2001087294-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-22 WO disclosed
WO-2001005398-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216449-A1 Phosphate transport inhibitors SLC34A2, SLC34A1, SLC34A3 SLC20A2 4/4885SLC20A1 5/4885MEN1 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.